The current PE ratio for Astrazeneca stock as of Apr 21, 2025 is 29.47. This is calculated based on the TTM EPS of $2.27 and the stock price of $66.9 per share. The PE ratio marks a decrease of 14% from its last 4 quarters average of 34.1.
The average historical PE ratio of Astrazeneca for the last ten years is 82.75. The current P/E ratio of 29.47 is 64% lower than the historical average. Looking back at the last ten years, AZN's PE ratio peaked in the Dec 2021 quarter at 1,456.25, when the price was $58.25 and the EPS was $0.04. The lowest point was in the Dec 2016 quarter, when it reached 19.65 with a price of $27.32 and an EPS of $1.39.
Maximum annual increase: 3,453.56% in 2021
Maximum annual decrease: -95.61% in 2022
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | 28.86 | -17.73% | $65.52 | $2.27 |
2023 | 35.08 | -45.15% | $67.35 | $1.92 |
2022 | 63.96 | -95.61% | $67.8 | $1.06 |
2021 | 1,456.25 | 3,453.56% | $58.25 | $0.04 |
2020 | 40.98 | -57.26% | $49.99 | $1.22 |
2019 | 95.88 | 114.59% | $49.86 | $0.52 |
2018 | 44.68 | 53.22% | $37.98 | $0.85 |
2017 | 29.16 | 48.4% | $34.7 | $1.19 |
2016 | 19.65 | -35.17% | $27.32 | $1.39 |
2015 | 30.31 | -57.8% | $33.95 | $1.12 |
2014 | 71.82 | 146.8% | $35.19 | $0.49 |
2013 | 29.1 | 205.35% | $29.69 | $1.02 |
2012 | 9.53 | 50.32% | $23.64 | $2.48 |
2011 | 6.34 | -23.15% | $23.15 | $3.65 |
2010 | 8.25 | -8.64% | $23.1 | $2.8 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Dec 2024 | 28.86 | -22.21% | $65.52 | $2.27 |
Sep 2024 | 37.1 | -1.07% | $77.91 | $2.1 |
Jun 2024 | 37.5 | 13.46% | $77.99 | $2.08 |
Mar 2024 | 33.05 | -5.79% | $67.75 | $2.05 |
Dec 2023 | 35.08 | -1.57% | $67.35 | $1.92 |
Sep 2023 | 35.64 | -0.89% | $67.72 | $1.9 |
Jun 2023 | 35.96 | -21.24% | $71.57 | $1.99 |
Mar 2023 | 45.66 | -28.61% | $69.41 | $1.52 |
Dec 2022 | 63.96 | -34.69% | $67.8 | $1.06 |
Sep 2022 | 97.93 | N/A | $54.84 | $0.56 |
Jun 2022 | N/A | N/A | $66.07 | -$0.53 |
Mar 2022 | N/A | N/A | $66.34 | -$0.43 |
Dec 2021 | 1,456.25 | 1,476.03% | $58.25 | $0.04 |
Sep 2021 | 92.4 | 122.12% | $60.06 | $0.65 |
Jun 2021 | 41.6 | 27.18% | $59.9 | $1.44 |
Currently, AZN's PE ratio is lower than its 3, 5 and 10-year averages.
In comparison to its peer LLY, AZN's PE ratio is lower, but it is higher than JNJ's and ABT's. Astrazeneca's PE ratio is trading above the peer average of 24.21.
Stock name | PE ratio | Market cap |
---|---|---|
BIIB Biogen Inc | 10.59 | $17.38B |
MRK Merck & Co Inc | 11.66 | $199.1B |
PFE Pfizer Inc | 15.85 | $127.57B |
ABT Abbott Laboratories | 17.17 | $228.45B |
NVS Novartis AG | 18.82 | $220.04B |
JNJ Johnson & Johnson | 26.99 | $379.44B |
AZN Astrazeneca plc | 29.9 | $210.47B |
LLY ELI LILLY & Co | 70.32 | $784.09B |
BMY Bristol Myers Squibb Co | N/A | $94.28B |
AZN stock has a price to earnings ratio of 29.47 as of Apr 21, 2025.
The 3-year average price to earnings ratio for AZN stock is 45.07.
The 5-year average price to earnings ratio for AZN stock is 131.58.
Over the last ten years, the quarterly PE ratio reached its highest level at 1,456.25 in the Dec 2021 quarter.
The current PE ratio of AZN is 64% lower than the 10-year historical average.
You can calculate the P/E ratio by dividing the most recent stock price by the trailing twelve months EPS. As of today (Apr 21, 2025), Astrazeneca's share price is $66.9. The company's earnings per share for the trailing twelve months (TTM) ending Dec 2024 is $2.27. Therefore, Astrazeneca's PE ratio for today is 29.47. PE RATIO(29.47) = STOCK PRICE($66.9) / TTM EPS($2.27)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.